Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?

The activation of the PI3K/AKT/mTOR pathway is a main driver of cell growth, proliferation, survival, and chemoresistance of cancer cells, and, for this reason, represents an attractive target for developing targeted anti-cancer drugs. There are plenty of preclinical data sustaining the anti-tumor a...

Descripción completa

Detalles Bibliográficos
Autores principales: Tarantelli, Chiara, Lupia, Antonio, Stathis, Anastasios, Bertoni, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7037719/
https://www.ncbi.nlm.nih.gov/pubmed/32033478
http://dx.doi.org/10.3390/ijms21031060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7037719/
https://www.ncbi.nlm.nih.gov/pubmed/32033478
http://dx.doi.org/10.3390/ijms21031060

Ejemplares similares